FTH: Oral multi-node inhibition demonstrates strong early efficacy and tolerability, with pivotal data expected soon
Multi-node inhibition targeting PI3K/AKT/mTOR shows promising efficacy and tolerability in early trials, with oral administration offering key advantages. Upcoming phase II data in endometrial cancer and ongoing breast cancer studies will inform future phase III plans and regulatory strategy.Based…